Cannabis and Cannabinoid Research最新文献

{"title":"Age Differences in Cannabis Consumption Patterns and in Associations Between Delta-9-Tetrahydrocannabinol Intake and Cannabis Use Disorders Among Adults with Daily Use.","authors":"Ofir Livne, Jacob Borodovsky, Alan J Budney, Caroline G Wisell, Mohammad I Habib, Cara A Struble, Lynn Chen, Jun Liu, Melanie Wall, Efrat Aharonovich, Deborah S Hasin","doi":"10.1177/25785125251360976","DOIUrl":"https://doi.org/10.1177/25785125251360976","url":null,"abstract":"<p><p><b>Introduction:</b> Cannabis use has risen disproportionately among middle-aged and older U.S. adults, groups particularly vulnerable to adverse effects, including cannabis use disorder (CUD). Consumption patterns have diversified in recent years. The quantity of cannabis use, historically measured in limited ways (e.g., number of joints), is now considered a key risk factor for CUD. However, age-related differences in consumption patterns and their relationships with CUD remain understudied. This study investigated age-related differences in consumption patterns and examined the relationship between quantity of use-measured by milligrams of THC (mgTHC)-and self-reported CUD in individuals with regular cannabis use. <b>Materials and Methods:</b> A total of 4134 U.S. adults (ages 18+; 45.9% male, 54.1% female) who reported daily cannabis use completed an online survey assessing cannabis consumption patterns and self-reported <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition's CUD criteria. Pearson's chi-square tests and one-way analysis of variance examined differences in sex, reasons for use, methods of consumption, CUD severity, criteria count, and mgTHC with comparisons across three age-groups (18-49, 50-64, 65+). Regression models, adjusted for sex and reasons for use, analyzed age-specific associations between mgTHC and CUD. <b>Results:</b> Overall, over 70% reported using cannabis for both medical and recreational purposes. Middle-aged adults were more likely to report medical use than younger ones (18.1% vs. 13.7%; <i>p</i> < 0.001) and older adults (14.1%; <i>p</i> = 0.027). Older adults were more likely to report recreational-only use compared with middle-aged adults (15.8% vs. 10.5%; <i>p</i> = 0.002). Smoking buds was the most common consumption method across age-groups, while high-potency concentrate use declined with age. In the overall sample, daily mgTHC was associated with CUD severity, and middle-aged and older adults endorsed fewer CUD criteria than younger adults at all levels of mgTHC; however, age effects were not statistically significant. <b>Discussion:</b> Among daily cannabis consumers, middle-aged and older adults differed from younger consumers in methods of consumption and reasons for use. While both groups consumed lower quantities than their younger counterparts, no age-related differences were observed in the relationship between mgTHC consumption and CUD, contrasting with evidence suggesting that older cannabis consumers may be more vulnerable to cannabis-related negative outcomes.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study.","authors":"Margaret Haney, Tse-Hwei Choo, Amy Tiersten, Frances R Levin, Alex Grassetti, Natasha DeSilva, Caroline A Arout, Diana Martinez","doi":"10.1089/can.2025.0028","DOIUrl":"https://doi.org/10.1089/can.2025.0028","url":null,"abstract":"<p><p><b>Introduction:</b> Taxane-induced peripheral neuropathy (TIPN) is experienced by most patients with breast cancer, and there is no efficacious treatment. In pre-clinical studies, co-administration of two constituents of cannabis, Δ⁹-tetrahydrocannabinol (THC) and cannabidiol (CBD), synergistically reduces TIPN. <b>Materials and Methods:</b> The goal of this 8-week, double-blind, randomized pilot study, conducted from 2019 to 2021, was to test the feasibility and tolerability of oral cannabis (100 mg CBD: 5 mg THC, TID) relative to placebo on pain resulting from TIPN. Participants with painful TIPN completed daily questionnaires online about their pain, sleep, and medication use, and weekly questionnaires on neuropathy. <b>Results:</b> All participants (12 women; 51 ± 6 years) randomized to placebo (<i>n</i> = 6) or active (<i>n</i> = 6) cannabis capsules completed the trial. Participants in both medication groups requested dose reductions (mean ± SEM capsules/day: placebo: 2.4 ± 0.4; active: 2.0 ± 0.4). In a preliminary evaluation of efficacy, measures of pain, pain interference, sleep, and functional well-being significantly improved over time (<i>p</i> < 0.03), but participants receiving cannabis had significantly higher ratings of neuropathy at each week (<i>p</i> < 0.035) and lower ratings of functional well-being in the last 3 weeks of treatment compared with participants receiving placebo (<i>p</i> < 0.02). Similarly, cannabis significantly worsened ratings of sleep and pain interference relative to placebo (<i>p</i> < 0.05). <b>Discussion:</b> This study demonstrates that: (1) double-blind, placebo-controlled testing of cannabis capsules in this dose range is feasible and well tolerated in women with TIPN and (2) ratings of pain, neuropathy, and well-being significantly improved over 8 weeks, but cannabis significantly worsened several endpoints relative to placebo. These findings highlight the necessity of placebo control when assessing the therapeutic utility of cannabis. Although there was no signal of efficacy herein, a fully powered study testing a range of cannabis doses for TIPN is warranted, given its impact on most patients with breast cancer, promising pre-clinical data, and the widespread use of cannabis among patients with cancer.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks of Cannabinoid Exposure on Birth Outcomes: A Systematic Review.","authors":"A Matthew Reck, Taylor Reilly, S Olivia Vanegas, Natalie J Shook, Steven G Kinsey, Sharon G Casavant","doi":"10.1089/can.2025.0027","DOIUrl":"https://doi.org/10.1089/can.2025.0027","url":null,"abstract":"<p><p><b>Introduction:</b> With the changing legal landscape, the acceptance and availability of cannabis products have increased. Cannabis products are generally considered \"natural\" and relatively safe by consumers. However, growing empirical evidence from humans and other animals indicates that cannabis negatively affects human health. In contrast to the well-known teratogenic effects of alcohol and tobacco products, the safety of cannabis product use during pregnancy has not yet been established. The goal of this systematic review was to determine the patterns that exist in human and rodent literature on the effects of prenatal exposure to cannabis products and delta-9-tetrahydrocannabinol (THC) on birth outcomes. <b>Methods:</b> A systematic review of rodent and human studies was conducted using PRISMA guidelines. Rodent search strategy used PubMed and Scopus with terms \"prenatal OR perinatal OR <i>in utero</i> OR maternal exposure AND cannabis OR THC or cannabinoids AND exposure NOT review NOT Human.\" Human search strategy used PubMed, CINAHL, and Scopus with terms \"cannabinoids OR cannabis OR THC OR marijuana\" AND \"pregnancy OR pregnant OR prenatal AND \"infant outcome OR infant health.\" After deleting duplicates and studies that did not fit the inclusion criteria, 21 rodent and 36 human studies were selected for review. Rodent studies focused on birth weight, litter size, mortality, and gestation length. Human studies have focused on birth weight, gestational age, and infant health at delivery. <b>Results:</b> In both human and rodent studies, prenatal exposure to cannabis was significantly associated with lower birth weight; however, it was not significantly associated with gestational age in rodents or humans. In most rodent studies, prenatal exposure to cannabis did not affect mortality or litter size. In human studies, there was a tendency for infants exposed to cannabis during pregnancy to have worse health at delivery. Findings indicate that cannabis exposure <i>in utero</i> may be associated with worse birth outcomes; however, the results are mixed and vary by species and outcome. <b>Discussion:</b> Methodological differences and scant existing research may have contributed to this inconsistency. Given the legalization of cannabis product use for recreational and medicinal purposes is growing, additional research is necessary to determine its influence on fetal and infant health outcomes.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Cannabidiol and Δ9-tetrahydrocannabinol on Anti-Inflammatory Lipid Mediator Synthesis in Humans.","authors":"Alan W J Morris, Raeghan L Mueller, Cristina Sempio, Jost Klawitter, Angela D Bryan, L Cinnamon Bidwell, Kent E Hutchison","doi":"10.1089/can.2024.0175","DOIUrl":"https://doi.org/10.1089/can.2024.0175","url":null,"abstract":"<p><p><b>Background:</b> Eicosanoids-lipid mediators derived from polyunsaturated fatty acids such as arachidonic acid-have a notable role in inflammatory signaling. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) have been shown in preclinical studies to modulate inflammatory pathways the modulating the enzymes that generate eicosanoids, namely lipoxygenase (LOX), cyclooxygenase (COX), and cytochrome P450 (CYP450). <b>Methods:</b> This present study aimed to investigate how CBD and THC effect plasma levels of eicosanoids generated through LOX, COX, and cytochrome P450 (CYP450) pathways. Using plasma sample data from multiple clinical studies, we tested the hypothesis that high-CBD cannabis use would increase eicosanoid levels compared with high-THC cannabis. <b>Results:</b> Following cannabis use, high-CBD cannabis led to a rise in plasma eicosanoids, particularly lipoxins, while high-THC cannabis did not. <b>Conclusions:</b> CBD promoted anti-inflammatory eicosanoid production <i>via</i> the 15-LOX pathway, therefore supporting the potential role of CBD as a therapeutic candidate for inflammatory diseases.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Thematic Text Analysis of Cannabis Edibles Brand Names.","authors":"Beth A Reboussin, Shelby Lake, E Alfonso Romero-Sandoval, Jennifer Cornacchione Ross, Kathleen L Egan, Kimberly G Wagoner, Erin L Sutfin, Cynthia K Suerken, Olivia E Horton, Allison J Lazard","doi":"10.1089/can.2025.0033","DOIUrl":"10.1089/can.2025.0033","url":null,"abstract":"<p><p><b>Introduction:</b> This study explores whether the cannabis edibles industry uses brand names that might impact consumer appeal and harm perceptions. <b>Materials and Methods:</b> An exploratory thematic text analysis of brand names for 1344 cannabis edible products from 250 brands advertised online between June and November 2022 was performed. Brands marketing only delta-9-tetrahydrocannabinol (THC) products (<i>n</i> = 80), THC and cannabidiol (CBD) products (<i>n</i> = 130), and only CBD products (<i>n</i> = 40) were compared. <b>Results:</b> Five core themes emerged: cannabis culture (42% of brands, <i>n</i> = 106), product characteristics (30%, <i>n</i> = 76), medicine and health (23%, <i>n</i> = 58), environment and nature (20%, <i>n</i> = 51), and identity and culture (14%, <i>n</i> = 34), with 15 subthemes. Brands only marketing CBD products more often had names with medicine and health (45%, <i>n</i> = 18) themes with subthemes of health and wellness (30%, <i>n</i> = 12) and expected effects (18%, <i>n</i> = 7) in contrast to brands marketing THC products (18%, <i>n</i> = 14; 2%, <i>n</i> = 2; 11%, <i>n</i> = 9 THC-only; 20%, <i>n</i> = 26; 5%, <i>n</i> = 6; 13%, <i>n</i> = 17 THC and CBD). Brands marketing THC products more often had names with cannabis (12%, <i>n</i> = 10 THC-only; 18%, <i>n</i> = 23 THC and CBD; 8%, <i>n</i> = 3 CBD-only) and spiritual/mystical (9%, <i>n</i> = 7 THC-only; 9%, <i>n</i> = 12, THC and CBD; 0%, CBD-only) subthemes. Food type subthemes were also more common among brands marketing THC products (19%, <i>n</i> = 15 THC-only; 21%, <i>n</i> = 27 THC and CBD; 8%, <i>n</i> = 3 CBD-only). Unconventionality (6%, <i>n</i> = 5 THC-only; 2%, <i>n</i> = 2 THC and CBD; 0% CBD-only) and names and places (16%, <i>n</i> = 13 THC-only; 5%, <i>n</i> = 8 THC & CBD; 5%, <i>n</i> = 2 CBD-only) were subthemes more common among brands only marketing THC products. <b>Conclusions:</b> This study identified distinct cannabis edibles brand name marketing strategies for THC versus CBD products that may affect consumer appeal and perceptions of harm, underscoring the need to monitor and potentially regulate cannabis edibles marketing to ensure that it does not mislead consumers or downplay potential risks.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Nabilone for the Treatment of Obesity: still Many Hurdles to Tackle.","authors":"Sebastiaan Dalle","doi":"10.1089/can.2025.0055","DOIUrl":"https://doi.org/10.1089/can.2025.0055","url":null,"abstract":"","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Substances of Health Concern: Label Accuracy of Cannabidiol and Tetrahydrocannabinol in Commercial Cannabidiol Tinctures from the United States.","authors":"Zander Sullivan, Coady Lapierre, Laura Weiser Erlandson, Linh Pham","doi":"10.1089/can.2025.0016","DOIUrl":"https://doi.org/10.1089/can.2025.0016","url":null,"abstract":"<p><p><b>Introduction:</b> In recent years, the production and consumption of cannabinoids have increased significantly. Researchers are particularly interested in cannabidiol (CBD), Δ⁸-tetrahydrocannabinol (Δ⁸-THC), and Δ⁹-tetrahydrocannabinol (Δ⁹-THC). Despite the growing prevalence of these molecules in everyday life, research shows that cannabinoid products are often mislabeled. In this study, we quantified and compared the label accuracy of CBD in full- and broad-spectrum tinctures to evaluate whether there is a public health concern related to CBD, Δ⁸-THC, and Δ⁹-THC. <b>Materials and Methods:</b> A total of 18 samples from different brands sold online in the United States were obtained for the study. Reverse-phase high-performance liquid chromatography with ultraviolet/visible light detection (RP-HPLC-UV) was employed to detect and quantify the concentration of CBD and THC isomers within the samples. Labels were deemed inaccurate if the actual concentration of CBD deviated by more than 10% from the labeled amount. <b>Results:</b> Our findings showed that 12 out of 18 samples had inaccurately labeled CBD concentrations. Notably, a significant difference in CBD label accuracy was observed between broad- and full-spectrum tinctures (<i>p</i> = 0.0282). No significant correlation was found between the cost of the tinctures and the label accuracy for CBD (<i>p</i> = 0.2117). While none of the broad-spectrum tinctures contained Δ⁸-THC, two contained Δ⁹-THC. All full-spectrum tinctures contained both Δ⁸-THC and Δ⁹-THC at levels below the federal limit for hemp of 0.3% on a dry weight basis. <b>Discussion:</b> Accurate labeling of CBD and THC in tincture products is a crucial public health concern, both locally in Texas and across the United States. There is a need for the U.S. Food and Drug Administration to promulgate regulations for labeling products that contain CBD and THC.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis Use in California Following Legalization of Recreational Use.","authors":"Linda Hill, Daniel Ageze, Renee Dell'Acqua, Alice Gold, Ilene Lanin-Kettering, Jill Rybar, Tom Shaughnessy, Sara Baird, Thomas D Marcotte","doi":"10.1089/can.2024.0179","DOIUrl":"https://doi.org/10.1089/can.2024.0179","url":null,"abstract":"<p><p><b>Introduction:</b> Cannabis was legalized in California for recreational use through the passage of Proposition 64: The Adult Use Marijuana Act of 2016. This analysis from the Impact 64 study describes the cannabis use patterns of adults 21 years and older in California since the passage of Proposition 64. <b>Methods:</b> An online questionnaire addressing use of tetrahydrocannabinol-containing cannabis (including frequency, product(s), length, source, and purpose) was administered from December 2022 to February 2023. Of the initial 15,309 census-weighted participants, a subset of participants completed a detailed cannabis use questionnaire, including 4,020 people who currently use cannabis. Cannabis users were grouped by use frequency, and chi-squared analysis was utilized for descriptive analysis. Multinomial logistic regression was applied to assess significant variables associated with specific use patterns. <b>Results:</b> Of the initial sample of 15,208, 37% reported current cannabis use (with use in the past 3 months), 30% formerly used cannabis, and 33% were nonusers. Among current users, 38% reported very frequent use (multiple times a day), 33% frequent use (four times per week to daily), and 30% occasional use (three times per week or less). Compared with occasional users, very frequent users were more likely to be male (65%, odds ratio [OR] = 1.8, <i>p</i> < 0.001), less educated (OR = 1.7, <i>p</i> < 0.001), and have lower incomes (under 50K vs 100K, OR = 2.3, <i>p</i> < 0.001). Most users reported multiple cannabis products, mainly flower inhalation (80%), vaping (66%), and edibles (61%), primarily sourced from dispensaries (77%), which the majority (94%) perceived as licensed. Of all current users, most used cannabis at home (93%) or for entertainment (75%), with many reporting use during creative activities (45%), with alcohol (36%) and/or with cigarettes (24%). Positive impacts were reported in mental (82%), emotional (81%), and physical (62%) health. The internet (51%) and friends/family (50%) were the main sources of information. Most current users felt comfortable discussing cannabis with their primary doctor (78%), although only 66% of primary doctors knew about recreational use. <b>Discussion:</b> There is a high prevalence of daily cannabis use among adult Californians, with most users obtaining products from perceived licensed dispensaries or delivery services. While most users feel comfortable discussing cannabis use with physicians, they primarily obtain information from other sources, highlighting the need to bridge this information gap.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Has Japan's Cannabis Control Act Been Amended?","authors":"Yuji Masataka, Yoshiyuki Akahoshi, Munenori Katayama, Futaba Umemura, Naoko Miki, Ryota Nakazawa, Kosuke Shibata, Chikako Yoshida, Ayako Mikami, Toshihiko Matsumoto, Kozo Akino, Ichiro Takumi","doi":"10.1089/can.2025.0006","DOIUrl":"https://doi.org/10.1089/can.2025.0006","url":null,"abstract":"<p><p><b>Background:</b> In 2023, Japan's Cannabis Control Act underwent its first major revision since its establishment in 1948. The legal framework surrounding cannabis had long remained rigid, with limited scope for medical or industrial applications. <b>Methods:</b> This review examines the content and implications of the 2023 legal amendments based on governmental documents, legislative records, and secondary analyses of regulatory shifts. The assessment focuses on three key domains: medical application, industrial use, and drug control. <b>Results:</b> Under the revised law, cannabis-derived products intended for medical use were brought under the same regulatory framework as opioid analgesics, theoretically enabling physicians to prescribe them. Simultaneously, the longstanding restriction limiting industrial use to mature stalks and seeds was lifted. However, this liberalization was counterbalanced by the introduction of a stringent THC threshold. On the criminal side, cannabis continues to be regulated as an illicit substance, and new penalties for use have been introduced. The revised law came into effect on December 12, 2024. <b>Conclusion:</b> The 2023 amendment represents a significant shift in Japan's cannabis policy, aiming to balance expanded medical and industrial opportunities with continued drug control. Its practical implications remain to be seen and warrant close monitoring in the coming years.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of Cannabidiol and Low-Dose Buprenorphine Suggests Synergistic Analgesia and Attenuates Buprenorphine-Induced Respiratory Depression.","authors":"Marisa S Briones, Dustin Z DeYoung, Keith G Heinzerling","doi":"10.1089/can.2025.0004","DOIUrl":"https://doi.org/10.1089/can.2025.0004","url":null,"abstract":"<p><p><b>Introduction:</b> As opioid-related drug overdoses remain a public health crisis, there is a critical need for innovative approaches to developing safer analgesics with improved safety profiles. BDH-001 is a fixed-dose combination of low-dose buprenorphine (BUP) and cannabidiol (CBD) being developed as a safer analgesic than currently available opioids. The purpose of this study was to examine the analgesic and opioid-sparing effects of BDH-001 and to complete an <i>in vivo</i> safety assessment in rats. <b>Methods:</b> Analgesic effect of BDH-001 was assessed using the chronic constriction injury model of chronic neuropathic pain with pain threshold assessed <i>via</i> Von Frey testing. Drug-drug interaction effects on pharmacokinetic (PK) parameters were assessed in a single dose PK study in rodents. The effects on respiratory depression were also assessed and confirmed in two separate rodent studies performing blood gas analysis and measuring O₂ saturation. <b>Results:</b> BDH-001 (combination of subanalgesic BUP dose and CBD) resulted in statistically significant increases in pain threshold compared to saline (<i>p</i> < 0.001), CBD alone (<i>p</i> < 0.01), and BUP alone (<i>p</i> < 0.05). The half-life of BUP was significantly shorter in the presence of CBD compared to BUP alone (<i>p</i> = 0.008), with no significant changes in any other BUP pharmacokinetic parameter assessed. CBD was found to attenuate BUP-induced respiratory depression in rats when assessing blood gases (<i>p</i> < 0.05) and O₂ saturation (<i>p</i> < 0.05) over several time bins. <b>Conclusions:</b> Data obtained in the present study indicate the addition of CBD to BUP was opioid-sparing and attenuated BUP- but not morphine-induced respiratory depression. There was no evidence these findings were the result of a PK interaction. Results support the hypothesis that BDH-001, a fixed-dose combination of BUP and CBD, may provide effective analgesia with a more favorable safety profile.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}